On 27 March 2026, SSY Group Limited announced that China’s National Medical Products Administration (NMPA) has granted production and registration approvals for two type 3 chemical drugs—Sodium Lactate Ringer’s Irrigation Solution (3000 ml) and Bumetanide Injection (2 ml:1 mg). Both products simultaneously passed consistency evaluation.
The Sodium Lactate Ringer’s Irrigation Solution represents the first such approval issued to a mainland Chinese enterprise, authorising its use for general rinsing applications where sterile electrolyte solutions are required.
Bumetanide Injection is indicated for the management of edema associated with heart failure and renal or hepatic dysfunction. Additional approved uses include prevention of acute renal failure as well as treatment of hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, SIADH and acute drug or toxin poisoning. The injection approval follows the Group’s 16 March 2026 registration approval for Bumetanide bulk drug, positioning it for immediate formulation and commercialisation.
SSY Group issued the statement as a voluntary update to keep shareholders and potential investors informed of its latest product-development milestones.
Comments